While Exact Sciences News Today

Exact Sciences (EXAS) delivered earnings and revenue surprises of 49.06% and 2.36%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

This company is finding success in fighting one of the deadliest illnesses.

This company is finding success in fighting one of the deadliest illnesses.

Diagnostic and cancer test products provider Exact Sciences Corp. (NASDAQ:EXAS) saw its shares spike over 17% on its Q1 2023 earnings results.

The stock is full of potential -- and risk.